In older, untreated AML patients not suitable for intensive chemotherapy, volasertib* combined with chemotherapy led to prolonged survival times compared to chemotherapy alone Volasertib* also …
In older, untreated AML patients not suitable for intensive chemotherapy, volasertib* combined with chemotherapy led to prolonged survival times compared to chemotherapy alone Volasertib* also …